person · Reporting owner
GROENHUYSEN WILHELMUS CM
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | June 28, 2024 | August 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 28, 2024 · Filed August 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 252,290 |
Reported balance
After 2024-06-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 1,055 · Balance 252,290 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 2,133 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.10 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.75 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.00 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.50 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2021 Filed Mar 4, 2021 22:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 23,004 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000029 · wf-form4_161489821134191.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,004 Underlying: Ordinary Shares · 23,004 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 23,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 12,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000029 · wf-form4_161489821134191.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,542 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:50 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,392 | $152.05 | $363,710.78 |
DisclosureSEC source: 0001645113-21-000029 · wf-form4_161489821134191.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,023 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Share Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 7,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000020 · wf-form4_161471946713217.xml · derivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,715 | $149.10 | $1,150,306.50 |
DisclosureSEC source: 0001645113-21-000020 · wf-form4_161471946713217.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 93 | $50.67 | $4,712.22 |
DisclosureSEC source: 0001645113-21-000002 · wf-form4_161014151569340.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,700 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2020 through December 31, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2020. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,262 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · derivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,262 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $110.89 | $22,177.00 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F5 · price: On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $110.85 to $110.92. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,813 | $110.24 | $199,865.12 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,807 F4 · price: On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,813 shares in multiple trades at prices ranging from $109.84 to $110.66. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,536 | $109.23 | $386,223.14 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,620 F3 · price: On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,536 shares in multiple trades at prices ranging from $108.84 to $109.82. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,513 | $108.49 | $272,645.42 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,156 F2 · price: On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,513 shares in multiple trades at prices ranging from $107.84 to $108.83. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $106.92 | $21,383.00 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,669 F1 · price: On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $106.74 to $107.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 8,262 | $7.48 | $61,799.76 |
DisclosureSEC source: 0001645113-20-000140 · wf-form4_160071932127330.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · derivative · entry 28 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,262 Underlying: Ordinary Shares · 12,500 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $110.52 | $11,052.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 24 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,500 | $109.81 | $164,707.50 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 23 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,707 F19 · price: On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,500 shares in multiple trades at prices ranging from $109.40 to $110.33. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,868 | $108.79 | $855,959.72 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 22 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,207 F18 · price: On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 7,868 shares in multiple trades at prices ranging from $108.37 to $109.28. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,232 | $107.94 | $240,910.92 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 21 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,075 F17 · price: On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,232 shares in multiple trades at prices ranging from $107.36 to $108.29. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $106.68 | $53,341.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 20 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,307 F16 · price: On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 500 shares in multiple trades at prices ranging from $106.33 to $107.02. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $105.28 | $31,584.60 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 19 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,807 F15 · price: On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 300 shares in multiple trades at prices ranging from $104.83 to $105.82. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $7.48 | $93,500.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 18 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · derivative · entry 27 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,762 Underlying: Ordinary Shares · 12,500 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,579 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · derivative · entry 26 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,579 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,933 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · derivative · entry 25 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,933 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 600 | $109.54 | $65,724.60 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 17 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F14 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 600 shares in multiple trades at prices ranging from $109.27 to $109.69. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $108.71 | $184,805.30 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 16 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,207 F13 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,700 shares in multiple trades at prices ranging from $108.27 to $109.22. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,123 | $107.66 | $551,557.55 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 15 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,907 F12 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 5,123 shares in multiple trades at prices ranging from $107.24 to $108.20. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,077 | $106.67 | $328,223.59 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 14 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,030 F11 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,077 shares in multiple trades at prices ranging from $106.24 to $107.23. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,000 | $105.80 | $211,600.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 13 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,107 F10 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,000 shares in multiple trades at prices ranging from $105.24 to $106.24. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $7.48 | $93,500.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $109.55 | $43,821.60 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F9 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 400 shares in multiple trades at prices ranging from $109.32 to $109.73. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $108.57 | $108,569.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,007 F8 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,000 shares in multiple trades at prices ranging from $108.17 to $108.99. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,279 | $107.65 | $352,977.79 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,007 F7 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,279 shares in multiple trades at prices ranging from $107.13 to $108.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,100 | $106.55 | $223,752.90 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,286 F6 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,100 shares in multiple trades at prices ranging from $106.13 to $107.08. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 800 | $105.62 | $84,492.80 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,386 F5 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 800 shares in multiple trades at prices ranging from $104.98 to $105.93. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,579 | $7.03 | $53,280.37 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $109.16 | $21,831.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F4 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $108.92 to $109.39. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 600 | $107.97 | $64,784.40 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,807 F3 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 600 shares in multiple trades at prices ranging from $107.78 to $108.21. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 633 | $107.18 | $67,847.47 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,407 F2 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 633 shares in multiple trades at prices ranging from $106.78 to $107.56. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $106.05 | $53,026.00 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,040 F1 · price: On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 500 shares in multiple trades at prices ranging from $105.46 to $106.44. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,933 | $7.03 | $13,588.99 |
DisclosureSEC source: 0001645113-20-000139 · wf-form4_160046143094928.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · derivative · entry 35 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,579 Underlying: Ordinary Shares · 12,500 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 13,368 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · derivative · entry 34 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,368 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · derivative · entry 33 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,933 Underlying: Ordinary Shares · 12,500 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · derivative · entry 32 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,262 Underlying: Ordinary Shares · 12,500 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,334 | $106.02 | $247,443.68 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · nonDerivative · entry 29 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F21 · price: On September 15, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,334 shares in multiple trades at prices ranging from $105.51 to $106.48. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,166 | $104.69 | $1,064,227.71 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · nonDerivative · entry 28 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,941 F20 · price: On September 15, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 10,166 shares in multiple trades at prices ranging from $104.45 to $105.43. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $7.48 | $93,500.00 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · nonDerivative · entry 27 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,368 | $104.45 | $1,396,287.60 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · nonDerivative · entry 26 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,607 F19 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 13,368 | $7.48 | $99,992.64 |
DisclosureSEC source: 0001645113-20-000136 · wf-form4_160029147743039.xml · nonDerivative · entry 25 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.